 1. Subjects with prostate cancer who demonstrate an anti-androgen withdrawal response, defined as a 25 drop in PSA within 4 weeks flutamide or six week nilutamide, bicalutamide of stopping a non-steroidal anti-androgen are not eligible until the PSA rises above the nadir observed after anti-androgen withdrawal. 